Remote Infection Control Assessments of US Nursing Homes During the COVID-19 Pandemic, April to June 2020.


Journal

Journal of the American Medical Directors Association
ISSN: 1538-9375
Titre abrégé: J Am Med Dir Assoc
Pays: United States
ID NLM: 100893243

Informations de publication

Date de publication:
06 2022
Historique:
received: 21 01 2022
revised: 23 03 2022
accepted: 30 03 2022
pubmed: 4 5 2022
medline: 9 6 2022
entrez: 3 5 2022
Statut: ppublish

Résumé

Nursing homes (NHs) provide care in a congregate setting for residents at high risk of severe outcomes from SARS-CoV-2 infection. In spring 2020, NHs were implementing new guidance to minimize SARS-CoV-2 spread among residents and staff. To assess whether telephone and video-based infection control assessment and response (TeleICAR) strategies could efficiently assess NH preparedness and help resolve gaps. We incorporated Centers for Disease Control and Prevention COVID-19 guidance for NH into an assessment tool covering 6 domains: visitor restrictions; health care personnel COVID-19 training; resident education, monitoring, screening, and cohorting; personal protective equipment supply; core infection prevention and control (IPC); and communication to public health. We performed TeleICAR consultations on behalf of health departments. Adherence to each element was documented and recommendations provided to the facility. Health department-referred NHs that agreed to TeleICAR consultation. We assessed overall numbers and proportions of NH that had not implemented each infection control element (gap) and proportion of NH that reported making ≥1 change in practice following the assessment. During April 13 to June 12, 2020, we completed TeleICAR consultations in 629 NHs across 19 states. Overall, 524 (83%) had ≥1 implementation gap identified; the median number of gaps was 2 (interquartile range: 1-4). The domains with the greatest number of facilities with gaps were core IPC practices (428/625; 68%) and COVID-19 education, monitoring, screening, and cohorting of residents (291/620; 47%). TeleICAR was an alternative to onsite infection control assessments that enabled public health to efficiently reach NHs across the United States early in the COVID-19 pandemic. Assessments identified widespread gaps in core IPC practices that put residents and staff at risk of infection. TeleICAR is an important strategy that leverages infection control expertise and can be useful in future efforts to improve NH IPC.

Sections du résumé

BACKGROUND
Nursing homes (NHs) provide care in a congregate setting for residents at high risk of severe outcomes from SARS-CoV-2 infection. In spring 2020, NHs were implementing new guidance to minimize SARS-CoV-2 spread among residents and staff.
OBJECTIVE
To assess whether telephone and video-based infection control assessment and response (TeleICAR) strategies could efficiently assess NH preparedness and help resolve gaps.
DESIGN
We incorporated Centers for Disease Control and Prevention COVID-19 guidance for NH into an assessment tool covering 6 domains: visitor restrictions; health care personnel COVID-19 training; resident education, monitoring, screening, and cohorting; personal protective equipment supply; core infection prevention and control (IPC); and communication to public health. We performed TeleICAR consultations on behalf of health departments. Adherence to each element was documented and recommendations provided to the facility.
SETTING AND PARTICIPANTS
Health department-referred NHs that agreed to TeleICAR consultation.
METHODS
We assessed overall numbers and proportions of NH that had not implemented each infection control element (gap) and proportion of NH that reported making ≥1 change in practice following the assessment.
RESULTS
During April 13 to June 12, 2020, we completed TeleICAR consultations in 629 NHs across 19 states. Overall, 524 (83%) had ≥1 implementation gap identified; the median number of gaps was 2 (interquartile range: 1-4). The domains with the greatest number of facilities with gaps were core IPC practices (428/625; 68%) and COVID-19 education, monitoring, screening, and cohorting of residents (291/620; 47%).
CONCLUSIONS AND IMPLICATIONS
TeleICAR was an alternative to onsite infection control assessments that enabled public health to efficiently reach NHs across the United States early in the COVID-19 pandemic. Assessments identified widespread gaps in core IPC practices that put residents and staff at risk of infection. TeleICAR is an important strategy that leverages infection control expertise and can be useful in future efforts to improve NH IPC.

Identifiants

pubmed: 35504326
pii: S1525-8610(22)00259-6
doi: 10.1016/j.jamda.2022.03.015
pmc: PMC8983607
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

909-916.e2

Investigateurs

Adesubomi Adeyemo (A)
Suparna Bagchi (S)
Karen Boone (K)
Katherine Allen-Bridson (K)
Susan Cali (S)
Clayton Carmon (C)
Zeshan Chisty (Z)
Nadezhda Duffy (N)
Lauren Epstein (L)
Neela D Goswami (ND)
D Cal Ham (DC)
Judy Hannan (J)
Margaret Hercules (M)
Anindita Issa (A)
Amy Kolwaite Arnp (A)
Jessie Legros (J)
Serina Lees (S)
Todd Lucas (T)
Almea Matanock (A)
Nancy McClung (N)
Pedro Moro (P)
Srinivas Nanduri (S)
Alicia Shugart (A)
Theresa Sipe (T)
Henrietta Smith (H)
Elizabeth Soda (E)
Tarah Somers (T)
Erica Umeakunne (E)
Pattie Tucker (P)
Katelyn White (K)

Informations de copyright

Published by Elsevier Inc.

Références

Health Aff (Millwood). 2021 Mar;40(3):384-391
pubmed: 33646872
Am J Infect Control. 2020 Mar;48(3):330-332
pubmed: 31911068
J Am Med Dir Assoc. 2020 Jan;21(1):97-103
pubmed: 31888867
J Am Med Dir Assoc. 2021 Jan;22(1):199-203
pubmed: 33321076
J Am Med Dir Assoc. 2021 Jun;22(6):1317-1321.e2
pubmed: 33309701
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-342
pubmed: 32214083
JAMA. 2020 Jul 7;324(1):23-24
pubmed: 32442303
J Am Med Dir Assoc. 2021 Nov;22(11):2378-2383.e2
pubmed: 33930318
Fed Regist. ;81(192):68688-872
pubmed: 27731960
J Am Geriatr Soc. 2018 Apr;66(4):742-747
pubmed: 29489017
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Infect Control Hosp Epidemiol. 2021 Aug;42(8):1020-1021
pubmed: 32753072
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
Health Aff (Millwood). 2020 Oct;39(10):1812-1821
pubmed: 32816600
Milbank Q. 2021 Jun;99(2):565-594
pubmed: 33590920
Infect Control Hosp Epidemiol. 2020 Jun;41(6):723-728
pubmed: 32252834
Infect Control Hosp Epidemiol. 2022 Mar;43(3):351-357
pubmed: 33736719

Auteurs

Maroya Spalding Walters (MS)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: vii0@cdc.gov.

Christopher Prestel (C)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lucy Fike (L)

Northrop Grumman Corporation, Falls Church, VA, USA.

Nijika Shrivastwa (N)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Janet Glowicz (J)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Isaac Benowitz (I)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Sandra Bulens (S)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Emily Curren (E)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Hannah Dupont (H)

CDC COVID-19 Healthcare Infection Control Team, Atlanta, GA, USA.

Perrine Marcenac (P)

CDC COVID-19 Healthcare Infection Control Team, Atlanta, GA, USA.

Garrett Mahon (G)

Eagle Global Scientific, LLC, San Antonio, TX, USA.

Anne Moorman (A)

CDC COVID-19 Healthcare Infection Control Team, Atlanta, GA, USA.

Abimbola Ogundimu (A)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lauren M Weil (LM)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

David Kuhar (D)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Ronda Cochran (R)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Melissa Schaefer (M)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Kara Jacobs Slifka (KJ)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Alexander Kallen (A)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Joseph F Perz (JF)

Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH